Welcome to AstraZeneca United States

letsvpn 手机版下载


letsvpn 手机版下载


letsvpn 手机版下载

Researching antibodies to target COVID-19

AstraZeneca is joining forces with government and academia with the aim of discovering novel coronavirus-neutralising antibodies. Harnessing internal expertise and via new collaborations, the aim is to identify monoclonal antibodies that have the potential to recognise, bind to and neutralise the SARS-CoV-2 virus, to decrease the impact of COVID-19.

View press release


letsvpn 手机版下载

Designation based on unprecedented results from the Phase III ADAURA trial where TAGRISSO reduced the risk of disease recurrence or death by c. 80%

letsvpn 手机版下载

FARXIGA significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type 2 diabetes

letsvpn 手机版下载

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies

letsvpn 手机版下载


letsvpn 手机版下载

letsvpn 手机版下载

letsvpn 手机版下载

兔子 turbo 加速器

The Path Forward, Evolving the Current Healthcare System

Important Discoveries in Asthma